

# Overview of Biomarkers for Tobacco Exposure

Mitch Zeller, JD → formerly FDA; now American Legacy Foundation

Notes:

Identify surrogate markers of potential harm & exposure

Biomarkers are scientific ~~variables~~.

Key regulatory issues:

- Comprehensive regulation (manufacture, adver., marketing/advertising)

- reduced harm products should undergo pre-market eval. of science by a technical regulatory authority

- Regulatory scrutiny of tobacco products; less scrutiny for cessation products

Topics of research → Demonstrate reduction in exposure → link that to reduced harm:

1) How to measure exposure reduction?

Do they exist? What steps should

be taken to measure mean total exposure

2) What studies are needed to

prove or disprove reduced exposure = red. harm?

3) re: unintended consequences: What can we do to minimize incentives for continuing to smoke?

4) Minimize incentives of non-smokers

or get them to quit

## Risk Perceptions

Need to link exposure to harm reduction

## Pre-market evaluation Scientific Claims

Report from NCI forthcoming